PRIMECAP Management acquired 472k LENZ Therapeutics shares worth $3.31M. That's 0.00% of their equity portfolio (287th largest holding). The investor owns 1.36% of the outstanding LENZ Therapeutics stock. The investor's estimated purchase price is $12.4M, resulting in a loss of 73%.